sacituzumab
gilead
['sacituzumab', 'mbc', 'bcsm', 'tropics-02', 'sacitu, govi']
tropics-02: sacituzumab govitecan vs tpc in hr+/her2- mbc median follow-up 12.8 mo pfs 5.5 vs 4.0 mo, hr 0.65 os (exploratory) 14.5 vs 11.2 mo, hr 0.79 less benefit if no visceral mets, but small subgroup. orr 21% vs 14% #asco23 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.